Machine Learning Identifies Candidates for Drug Repurposing in Alzheimer's Disease

ABSTRACT: Clinical trials of novel therapeutics for Alzheimer's Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication is a more rapid and less expensive option. In this study, we profile 80 FDA-approved and clinically tested drugs in neural cell cultures, with the goal of producing a ranked list of possible repurposing candidates.

ORGANISM(S): Homo sapiens

PROVIDER: GSE164788 | GEO | 2021/01/14

REPOSITORIES: GEO